Thiazolidinediones Pretreated Bone Marrow-Derived Mesenchymal Stem Cells As An Anti-Cancer Approach Against Mcf-7 Breast Cancer Cell Line

• Main Author: Lim, Shern Kwok
• Format: Thesis
• Language: English
• Published: 2022
• Subjects: R5-920 Medicine (General)
• Online Access: http://eprints.usm.my/59708/1/24%20Pages%20from%20LIM%20SHERN%20KWOK%20-%20TESIS.pdf; http://eprints.usm.my/59708/

Breast cancer is the most prevalent type of cancer among women globally. Although treatments are currently available, most of these therapies are associated with adverse effects. For that reason, new treatment strategies utilising approved drugs may prove to be beneficial. Pioglitazone (PIO) and rosiglitazone (ROSI) are thiazolidinediones (TZDs) drugs that are clinically used to treat type 2 diabetes mellitus. Although PIO and ROSI have been linked to several adverse effects, there have been reports about their anti-cancer properties. For that reason, this study was conducted to improve the overall efficacy of TZDs therapy by utilising PIO and ROSI in combination to treat MCF-7 breast cancer cells. Additionally, the study also investigated the combination therapy of PIO and ROSI as a pretreatment strategy for bone marrow-derived mesenchymal stem cells (BM-MSCs) to indirectly treat MCF-7 cells via cell-cell interaction. The results revealed that PIO and ROSI when used in combination, induced higher inhibition of cell viability with lower levels of cellular lipid accumulation in MCF-7 cells at 48 and 96 hours of co-culture. Furthermore, the viability of TZDs pretreated BM-MSCs remained uninhibited for up to 96 hours and no signs of cell stress or death was observed at Day 7.